Jump to content

Fletikumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:14, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fletikumab
Monoclonal antibody
Type?
TargetIL20
Clinical data
Other namesNNC0109-0012
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6494H10000N1728O2050S44
Molar mass146492.12 g·mol−1

Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis.[2]

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fletikumab&oldid=963846721"